Archives: BioMedWire

December 15, 2020 15:03:28

Precision oncology leverages the profile of genetic mutations in patients for the purpose of delivering precision drug-based cancer therapy
Precision oncology industry forecast to be worth 99.72 billion by 2027 according to recent report
POAI applies AI to proprietary data trove, aiding oncologists in personalizing cancer therapies in addition to collaborating with pharmaceutical companies for drug discovery

Precision oncology is driven by the profile of genetic mutations in tumors that give practitioners required information to target therapies based off the specific mutations in the patient’s tumor. According to a recent research report, the industry is predicted to be worth 99.72 billion by 2027 as a result of synergistic efforts between big data healthcare organizations and pharmaceutical companies (https://ibn.fm/ss0Ez). Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery for cancer, is positioned to play a critical role in industry growth through its integration of AI technology into oncologists’ clinical decision-making processes, paving the way for better health outcomes.

Recent advances in cancer care have been closely associated with genomic medicine, fueled by research confirming correlations between specific genetic mutations and several tumors and tumor types. These advances hold promise for oncologists who use…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Way2Grow (‘W2G’) Biopharma Company Announces Entry into Cannabis Productivity, Plans for Psychedelic Research and Development

December 15, 2020 14:41:51

Way2Grow Nurseries (“Way2Grow” or “W2G”), a privately held biopharma company, today announced its entry into the productivity phase of cannabis cultivation, micropropagation and extraction. The company also announced its preparation of a Health Canada application towards psychedelic research and development for a medicinal mushroom (Psilocybe semilanceata) Dealer Licence and a Section 56 Exemption for use of psilocybin production and extraction for planned preclinical research under scientific purposes, per the Controlled Drugs and Substances Act (the “CDSA”). According to the update, W2G has secured approval for a single-story production facility designed to support tissue culture and micropropagation and to meet organic cannabis cultivation, processing and medical sales requirements. The company’s plans include expansion of its bio-pharmaceutical and bio-nutraceutical research laboratory, the addition of controlled rooms for the cultivation production, extraction and formulation of psilocybin mushrooms (Psilocybe semilanceata), as well as the addition of a medical dispensary in Osoyoos, British Columbia.

To view the full press release, visit https://ibn.fm/jKOm8

About Way2Grow Nurseries (“W2G”)

Way2Grow is a privately held biopharmaceutical company in the cannabis and psychedelic industries. W2G began with an organic vision to help patients gain better access to high quality, consistent, organic products. To achieve this vision, W2G has developed a consistent phyto-pharmaceutical feedstock growth plan through the use of tissue culture and molecular biology. These methods allow for the standardization of the procedures used to ensure quality and consistency of W2G’s biopharmaceuticals.

W2G’s extensive research and IP approach is focused on the development of several new plant-based cultivation techniques, hybrid cultivar development, genetic profiling and tissue culture. By developing a molecular breeding and genetics program, W2G can identify new bioactive compounds to determine interactions with specific genes responsible for chronic diseases.

Way2Grow is located in Osoyoos, British Columbia, and is regulated under the Cannabis Act and the Cannabis Regulations (Canada). For more information, visit the company’s website at www.W2G.ca.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Human Evolution May Be Responsible for Increased Risk of Developing Cancer

December 15, 2020 14:05:50

Even in the absence of risk factors such as the use of tobacco and genetic predisposition, human beings are susceptible to developing tumors that lead to colorectal, lung, prostate and breast cancers. A study led by researchers from UC San Diego in collaboration with the Moores Cancer center explains why this is so.

The study suggests that a unique evolutionary gene mutation may partly be…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Launches Regulation A+ Offering

December 15, 2020 12:14:21

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has launched a Regulation A+ equity crowd-funding campaign. The announcement follows the qualification by the U.S. Securities and Exchange Commission of BRSF’s Form 1-A offering. The intended purpose of the offering is to provide both accredited and non-accredited potential investors an opportunity to support the company in its efforts to more fully introduce its proprietary technologies to the neurology market. Through its Reg A+ offering, Brain Scientific will sell units at $9 each, with a minimum investment of $500. The units are comprised of five shares of common stock and one warrant to purchase common stock, and investments can be made by check, ACH payments, wire transfer or major credit cards. The offering follows the launch of BRSF’s innovative NeuroCap, a disposable, pre-gelled, hospital-grade EEG headset that can be easily and quickly applied by almost any member of a clinical staff. “Our Regulation A+ offering will showcase our company to a much broader pool of potential investors, opening the door for additional growth opportunities to continue our work in providing needed solutions for optimal care and efficiency in neurology,” said Brain Scientific chairman Boris Goldstein in the press release. “With the wide-scale availability of NeuroCap, now is the time for Brain Scientific to attract new investors who support our mission to modernize the brain diagnostic market and bridge the gap in neurological care.”

To view the full press release, visit https://ibn.fm/SuKGZ

About Brain Scientific

Brain Scientific is a commercial-stage, health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information about the company, please visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – LexaGene (TSX.V: LXG) (OTCQB: LXXGF) Announces PO from Ethos Discovery for Proprietary MiQLab

December 15, 2020 11:23:32

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, received a purchase order (“PO”) from Ethos Discovery for its exclusive MiQLab(TM). Designed for use in veterinary hospitals, MiQLab features an automated, easy-to-use system and rapid, in-hospital identification of pathogens. That information is invaluable for veterinarians as they make patient-care decisions. LexaGene’s MiQLab tests samples using real-time PCR, which is recognized for its sensitivity and specificity. “Up until now, veterinarians have had limited options for infectious disease testing,” said LexaGene CEO and founder Jack Regan, MD, in the press release. “Generally, veterinarians send collected samples to reference laboratories and wait up to 5 days or more to receive the results. This slow turn-around time and delay in proper treatment can be frustrating to many veterinarians and potentially harmful to their patients. With the MiQLab, we are changing veterinary diagnostics. Veterinarians will now have the opportunity to adopt an automated, rapid, in-hospital, reference laboratory quality testing solution so they can deliver world-class care. We are gaining traction by steadily building momentum with MiQLab in the veterinary market and are looking forward to meeting the demand and fulfilling orders in 2021.”

To view the full press release, visit https://ibn.fm/Ob6mX

About LexaGene Holdings Inc.

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com.

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Discover How Coronavirus Triggers Silent Hypoxia

December 14, 2020

December 14, 2020 14:20:16

There are some aspects of the coronavirus that scientists do not know enough about, seeing as it’s a completely new virus that attacks the lungs as well as other parts of the body. However, the strides that have been made in the last few months with regard to research — and now a vaccine — are a clear indication that researchers are working hard to discover as much as they can.

Recently, University of Vermont collaborators and biomedical engineers from Boston University discovered have studied how the coronavirus causes…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Innovative Technology to Change Current Standard of Care for Bladder Cancer Patients

December 14, 2020

December 14, 2020 13:35:55

The company’s proprietary technology could change the way surgeons handle cystoscopy procedures by displaying white light and blue light images side-by-side on one screen
The technology is primarily promoted as an imaging device for bladder cancer but has the potential to expand to other endoscopic procedures including laparoscopic, colorectal and thoracic
Bladder cancer is the sixth most prevalent cancer in the United States, with 600,000 people fearing recurrence
The global market for bladder cancer is estimated to grow to an estimated $4.71 billion by 2026

The current standard of care for bladder cancer is minimally invasive surgery (MIS)uses white light to illuminate the cancer in the bladder. The 30-year-old white light method is highly effective for visualizing the cancerous tumors that protrude above the bladder’s wall. Unfortunately, it is difficult to distinguish flat tumors from normal tissue and the margins of the tumor are almost impossible to visualize with the current standards.

The introduction of blue light in combination with a fluorescent contrasting druglight has been a game-changer in the industry, with one major exception – it cannot be used in real-time. Surgeons are required to flip between the white light and…

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Strategic Board Appointment

December 14, 2020

December 14, 2020 11:01:40

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced the appointment of David M. Borecky, vice president and chief accounting officer of Impossible Foods, to its board of directors. According to the update, David will leverage his extensive global relationships in the plant-based innovation community to accelerate and raise awareness of MustGrow’s remarkably safe and effective plant-based crop protection technologies. “David’s strong connections within the Silicon Valley and plant-based culture communities will prove instrumental in our development of plant-based biopesticides for a sustainable food supply,” said MustGrow Chairman Brad Munro. “A director of David’s calibre is an exciting addition to the MustGrow team, particularly his prowess in large global corporate M&A transactions.”

To view the full press release, visit https://ibn.fm/XPWeK

About MustGrow Biologics Corp

MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits and vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit and vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. The company has approximately 37 million basic common shares issued and outstanding. For further details, please visit www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Engages Dalmore Group for Expert Strategic Advice, Innovative Solutions

December 11, 2020 14:47:24

Brain Scientific (OTCQB: BRSF), a commercial-stage health-care company focused on developing innovative and proprietary medical devices and software, recently entered into a strategic partnership with the Dalmore Group. A member of FINRA and SIPC, the Dalmore Group maintains an active presence in the Regulation A+ equity funding space. The company is one of the world’s most active broker-dealers and has served on more than 50 RegA+ offerings in the past 12 months, raising more than $1 billion of capital in 2019. The Dalmore Group secures the majority of its clients by referral from securities attorneys and industry participants. A recent article discussing this indicates that BRSF is looking to the company for its expert strategic advice and innovative solutions. “We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein of the collaboration. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states.”

To view the full article, visit https://ibn.fm/eRrYM

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

December 11, 2020 14:36:30

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative and effective therapies are needed. CF is a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. Technological advances have greatly increased the life span for CF patients. While children with CF rarely made it to elementary school age in the 1950s, the median age of survival for a CF patient is now around 47 years, with many patients living into their 60s (https://ibn.fm/RQcG4). A recent article discusses AZRX’s positioning amid the work in targeted treatments. It reads, “Due to the efforts of companies such as AzurRx BioPharma, the life span and quality of life of CF patients could be further improved. AzurRx’s lead product is MS1819, a recombinant lipase that could potentially change the treatment of exocrine pancreatic insufficiency in CF and CP patients.”

To view the full article, visit https://ibn.fm/8V7rO

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specializing in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – GC Pharma’s Promising Research, Shincheonji Church Plasma Drive Offer Ray of Hope for Latin American COVID-19 Patients

December 11, 2020 13:42:46

GC Pharma and Shincheonji Church are offering assistance for the Latin American countries ravaged by the COVID-19 pandemic. A recent breakthrough in GC Pharma’s COVID-19 research was achieved on Dec. 6, 2020, when a COVID-19 patient recovered after receiving GC Pharma’s blood plasma therapy. The therapy, GC5131, was developed by fractioning an antibody with the immunogenicity from the plasma of a recovered COVID-19 patient. Many Latin American hospitals already use GC Pharma’s IVIG-SN treatment to save patients from various illnesses, and this breakthrough may also open doors for GC Pharma’s blood plasma therapy to be administered to Latin American COVID-19 patients. In addition, Shincheonji Church provided a boost to GC Pharma’s COVID-19 treatment research through large-scale plasma donations. A total of 4,000 Shincheonji members are expected to participate in the plasma donation, which is now in its third round. “For the people around the world, [donating our blood] for a cure is the most valuable thing we can do after recovering from COVID-19,” said a member of Shincheonji Church.

To view the full press release, visit https://ibn.fm/YSP8m

About GC Pharma

GC Pharma, a biotechnology pioneer in South Korea, is now preparing to take another major leap forward toward ensuring a healthier and happier future for all peoples worldwide. Challenge and innovation, care and compassion, transparency and integrity, and respect and dedication are the core principles that guide GC Pharma on its journey toward achieving its next goal. For more information, visit www.GlobalGreenCross.com.

About Shincheonji Church

Shincheonji, Church of Jesus, the Temple of the Tabernacle of the Testimony, commonly known as Shincheonji Church, Shincheonji Church of Jesus or simply Shincheonji, is an offshoot Christian new religious movement established in South Korea by Lee Man-hee. For more information, visit http://en.Shincheonji.kr.

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

What You Should Know About Chronic Rhinitis

December 11, 2020 13:20:12

Ever heard of chronic rhinitis? No? Well, it’s a condition that results in the inflammation of the inner lining of your nose. It can last for more than a month, and statistics show that 77 million individuals in America have the disease. Chronic rhinitis is not acute rhinitis, which only lasts several days.

There are two types of chronic rhinitis: the non-allergic and allergic types. An estimated 19 million individuals in America suffer from the…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Brain Cancer Drug IND Filing Accepted for Review by FDA

December 10, 2020 12:48:24

CNS Pharmaceuticals featured in audio broadcast distributed to thousands of syndication points.
Berubicin IND accepted for review by FDA
Phase 1 trial showed 44% of patients experiencing clinical benefit of stable disease or better
Adult Phase 2 trials to commence in Q1 2021

The IND filing for brain cancer drug Berubicin has been accepted for review by the U.S. Food and Drug Administration (“FDA”), reports CNS Pharmaceuticals (NASDAQ: CNSP), the company now responsible for the drugs’ development. That news was featured in a recent syndicated NetworkNewsAudio (“NNA”) broadcast, which covered CNS Pharmaceuticals’ recent submission of an Investigational New Drug (“IND”) application to the FDA for Berubicin. The broadcast also detailed the company’s plans to commence adult Phase 2 trials of the drug during the first quarter of 2021.

Since review of the IND application has not been completed, it may seem a little strange that CNSP is already looking ahead to Phase 2 clinical trials. However, Berubicin has already been the subject of Phase 1 trials, which are focused on…

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

How to Prevent Injuries During Your Workout

December 10, 2020 12:35:44

People work out for different reasons. Some want to keep fit and healthy whiles others have aesthetic in mind; still others may be training for an upcoming competition or event. Doctors recommend working out to maintain good health, advising that we make it part of our daily routines. A good workout plan should factor in the risk of injury and how to avoid it. Injuries only impede your progress. To avoid this, here are some ways you can avoid injuries whe working out.

Stretch and do warm-up exercises before you begin.

Taking a few minutes to warm up helps your muscles…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Predictive Oncology (NASDAQ: POAI) Releases Third-Quarter 2020 Business Update, Financial Report

December 10, 2020 12:29:56

Financial numbers show revenues stay level, gross margins up and operations expenses down.
Company continues focus on primary mission of applying artificial intelligence to precision medicine, drug discovery.
POAI subsidiaries all showing progress, growth in key areas.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its Q3 2020 financial report along with an update of company accomplishments and achievements (https://ibn.fm/HCpQM). In the report, POAI CEO Dr. Carl Schwartz noted milestones for each of the company’s subsidiaries: Helomics, TumorGenesis, Soluble Biotech and Skyline Medical.

“Our operating cash improved over the first nine months of 2020 as a result of an improvement in operating expenses, if the non-cash expense for goodwill impairment is excluded, continued new sales of our STREAMWAY Systems, which provide an annuity-like revenue stream from ongoing sales of disposables, and proceeds from equity offerings, indicating investor confidence in…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD

December 10, 2020 10:46:09

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual Property Office (“KIPO”) for one of its treatments for depression. VistaGen received notification that KIPO has issued a decision to grant Patent Application No. 10-2015-7020176. The patent relates to VistaGen’s PH10, an investigational neuroactive nasal spray designed to have rapid-onset therapeutic potential in a variety of neuropsychiatric indications involving depression; the patent will not expire earlier than 2034. VistaGen is currently preparing for Phase 2B clinical development of PH10 as a potential stand-alone, rapid-onset treatment for major depressive disorder (“MDD”). “The Republic of Korea is an important pharmaceutical market,” said VistaGen CEO Shawn K. Singh in the press release. “With counterpart patents already issued in the U.S., Greater China , Europe and Japan, this patent enhances our patent protection for PH10 and is a key component of our global commercial protection strategy for PH10.

To view the full press release, visit https://ibn.fm/RmBaj

About VistaGen Therapeutics Inc.

VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.Vistagen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

December 10, 2020 09:51:12

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price target at initiation of coverage. The report reads, “We initiate PCSA with a Speculative Buy rating as we consider the two leading assets in PCSA’s pipeline portfolio as most promising and with potential value. Eniluracil probably can reduce adverse events and improve efficacy of 5-FU/capecitabine that are standard-of-care for multiple cancer indications. Another asset, deuterated pentoxifylline, may help patients with ulcerative necrobiosis lipoidica, a skin disorder with no FDA-approved agents, to heal the ulcers in an expedient way. While we keep our current PoS at 20%, as PCSA moves forward in clinical development the value of the company should grow accordingly, in our opinion.”

To view the full report, visit https://ibn.fm/9GWkG

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company used these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

RYAH Group Inc. Is ‘One to Watch’

December 9, 2020 14:29:35

RYAH Group is a technological leader in the plant-based treatment market with its unique combination of proprietary IoT devices and data analytics, supported by patented AI technology
The company’s products pair a growing ecosystem of therapeutic plants with top-rated apps, devices and services
RYAH offers a complete remote dosage delivery and dose-monitoring platform based on data-driven analytics supported by prescribing doctors and their patients
The company is finalizing its anticipated listing on the Canadian Securities Exchange
RYAH holds a unique position on the $100.3 billion medical plant market, with the potential to capture footholds in both the IoT and Data Intelligence industries

RYAH Group is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.

The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and…

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Georgia State Researchers Develop Drug That Can Stop Coronavirus Transmission

December 9, 2020 14:05:34

Scientists at the Georgia State University Institute for Biomedical Sciences have found that the MK-4482/EIDD-2801 antiviral drug, which was developed to treat the SARS-CoV-2 infection, completely stops transmission of the virus in 24 hours.

The researchers, led by distinguished Georgia State University professor Dr. Richard Plemper, initially discovered that…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific Inc. (BRSF) New Management to Play Key Role in Advancing Commercialization, Growing Revenue

December 9, 2020 14:02:54

BRSF enhances executive team with new strategy, marketing VPs.
New market opportunity created with demand for remote EEG testing due to COVID-19.
Brain Scientific has developed NeuroCap(TM), a revolutionary, hospital-grade disposable EEG headset.

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, strengthened its executive team with the appointment of two proven sales and marketing figures. The two management additions include Amy Griffith, the new vice president of strategy and business development, who will lead the development of strategic and tactical initiatives (https://ibn.fm/Stz6j), and Stuart Bernstein, the new vice president of marketing, who will be responsible for BRSF’s marketing strategy (https://ibn.fm/yfZYU).

The strategic move is designed to drive Brain Scientific’s revenue growth and expand its commercialization programs by leveraging the newly hired key executives’ wealth of experience and knowledge. As a commercial-stage, healthcare company disrupting the brain diagnostics market, Brain Scientific is committed to the rapid deployment of its unique technology, bringing its NeuroCap, a…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting

December 9, 2020 13:43:09

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote in favor of the proposals being considered at the special meeting, primarily because the reincorporation in Nevada will eliminate its obligation to pay the injurious annual Delaware franchise tax, currently equal to approximately $170,000 per year. Predictive Oncology can save approximately $158,000 annually in state taxes by reincorporating in Nevada.

To view the full press release, visit https://ibn.fm/wMinE

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Participate at LD Micro Main Event

December 9, 2020 13:14:03

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that Dr. Jack Regan, LexaGene’s CEO and founder, will present at the 13th Annual LD Micro Main Event Conference. Interested parties should visit https://ibn.fm/tKpNj to register for the event, slated to be held on Dec. 15, 2020. In addition, the company announced that it has engaged Native Ads Inc. of New York to perform strategic digital media, marketing and data analytics services including, but not limited to, content development, video production and editing, website development, media buying and distribution, and campaign reporting and optimization. According to the update, the 12-month campaign is scheduled to begin in January 2020.

To view the full press release, visit https://ibn.fm/bF2XE

About LexaGene Holdings Inc.

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press “go.” The MiQLab(TM) system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information, visit the company’s website at www.LexaGene.com.

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes ‘Most Exciting Thing That I’ve Done’ on Gamechangers LIVE

December 9, 2020 11:52:59

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in a Phase I clinical trial. As a result of the trial, 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS recently submitted an Investigational New Drug (“IND”) application with the FDA, and, pending approval, it intends to commence a pivotal Phase II clinical trial in the U.S. “I have done all kinds of different things in my career, been in the health care industry for a long time. This is the most exciting thing that I’ve done,” Climaco said in the interview. “This company and our lead product have the potential to really change the landscape and the game in an area of oncology that hasn’t seen a lot of hope for a very long time in glioblastoma.”

To view the full press release, visit https://ibn.fm/Swa22

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Live Investor Webcast; Provides Overview of Biopesticide Pipeline

December 9, 2020 10:53:24

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has provided an update of its natural plant-based, mustard-derived biopesticide technology product pipeline. The company is intent on using the natural defense mechanism of the mustard seed to develop and commercialize biopesticide technologies; MustGrow is using the technology to control diseases, pests and weeds. The company is planning a live investor webcast today to discuss upcoming catalysts; the webcast is slated to begin at 11 a.m. ET. Anyone interested in attending should sign in five minutes early. Participants will be anonymous and muted, but questions can be sent to the company ([email protected]) before the event for consideration. MustGrow is planning to use its patented biopesticide technologies to disrupt global agriculture markets that are primarily using potentially dangerous chemistry-based products. The company’s patent portfolio includes both method-of-use and composition-of-matter claims for MustGrow’s exclusive mustard-derived method to fight weeds, pests and diseases. With the global banning or deregistration of many synthetic chemicals, MustGrow sees an opportunity. A recent report by Markets and Markets forecasts the global biopesticide market size doubling in size to an estimated $8.5 billion by 2025.

To attend the live webcast, visit https://ibn.fm/xtPRT

To view the full press release, visit https://ibn.fm/2MUNq

About MustGrow Biologics Corp.

MustGrow is a publicly traded, agriculture biotech company focused on providing natural, science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a U.S. EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s Pest Management Regulatory Agency (“PMRA”) as a biopesticide for high-value crops, including fruits and vegetables. MustGrow has now concentrated a liquid format, TerraMG, that with regulatory approval could be applied through standard drip or spray equipment, improving functionality and performance features. In addition, this new mustard-derived technology could have other applications in several different industries from pre-plant soil treatment to post harvest disease and pest control. The company has approximately 37 million basic common shares issued and outstanding. For more information about the company, please visit www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Shines Spotlight on Clinical Design for Upcoming Phase 2 Trial

December 8, 2020 14:17:57

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing a drug candidate it hopes will beat the deadly brain cancer Glioblastoma Multiforme (“GBM”). The company recently announced that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review and discussed a novel clinical design for its upcoming Phase 2 U.S. trial in a webinar open to the public. “I would like to remind everyone that this upcoming Phase 2 trial will build on the success of the Phase 1 trial of Berubicin in which the clinical benefit response was 44%, including one patient … who had a durable complete response and is still alive and cancer-free today, 14 years after treatment with Berubicin, and another two patients with partial responses, who had reductions of greater than 25% in the size of their tumors,” CNS Pharmaceuticals CEO John Climaco told the webinar audience.

To view the full article, visit https://ibn.fm/UGq02

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the United States, while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. The company’s second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Solution Shaves Time, Money to Optimize Therapeutic Formulations

December 8, 2020 14:01:14

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Through its subsidiary Soluble Biotech, the company delivers a solution that reduces the cost, time and manpower needed to optimize therapeutic formulations. A recent article discussing this reads, “HSC Technology is a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens, using additives and excipients commonly included in protein formulations (https://ibn.fm/QPo4W). The data generated from these screens is analyzed by a predictive algorithm used to identify the optimal combination of additives and excipients, resulting in increased solubility and physical stability of proteins. And while the technology produces unparalleled optimization results, it provides other benefits as well.”

To view the full article, visit https://ibn.fm/5qPG1

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Is ‘One to Watch’

December 8, 2020 13:29:18

Imagin Medical Inc. uses the standard levels of care for bladder tumor resection and adds advanced technology combined with an FDA-approved imaging agent to display images side-by-side in real-time to provide better cancer visualization, potentially leading to less recurrence
Hospitals can use their existing endoscopic equipment, as the company’s technology is compatible with almost every model on the market
The i/Blue™ Imaging System can potentially be used for other minimally invasive procedures, accommodating multiple contrast agents and illumination sources
Bladder cancer contributes to 4.5% of all new cancers diagnosed and 3% of all cancer-related deaths. It is the sixth most prevalent form of cancer in the United States, with a greater than 50% risk of recurrence
The company is led by a management team with experience in this industry, including minimally invasive surgery and medical device implementation

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures. Its initial focus is on bladder cancer.

The company’s first product is the i/Blue Imaging(TM) System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons’ ability to…

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Finalizes Technology Transfer of Manufacturing Process for Novel Gene Therapy

December 8, 2020 11:18:29

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has reached a significant milestone. The company successfully completed the technology transfer of its manufacturing process for the production of its lead candidate for immunogene therapy, REQORSA(TM). The transfer was made from the major cancer research institution where it had previously been manufactured to experienced, commercial contract development and manufacturing organizations (“CDMOs”). This step marks the first time REQORSA has been manufactured outside of the research institution where it was discovered and at commercial scale in a current Good Manufacturing Practices (“cGMP”)-compliant facility. According to the company, the move will provide production and process improvements that will result in a reliable, scalable, reproducible and stable drug product suitable for storage, shipment and patient use. “The successful completion of our manufacturing technology transfer represents a major milestone for Genprex,” said Genprex president and CEO Rodney Varner in the press release. “We are delighted to collaborate with leading, global CDMOs that have enabled us to complete the successful engineering batch. We are now focused on the completion of commercial scale production of REQORSA, for use in our two upcoming clinical trials. At the same time, our clinical group is engaging with clinical trial sites who will recruit and treat patients related to our clinical trials.”

To view the full press release, visit https://ibn.fm/BVPes

About Genprex Inc.

Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with “EFGR” mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Coronavirus May Be Worsening Mental Health Conditions in Nursing, Pregnant Women

December 8, 2020 11:05:11

A recent study reported in “Psychiatric Review” by researchers from Brigham and Women’s Hospital showed that women who were pregnant or had given birth recently had significant rates of PTSD, depression and generalized anxiety symptoms. These symptoms were worsened by various health worries and coronavirus-related grief.

Prior research has shown that 10% to 20% of women who are pregnant experience various mental health issues in the weeks before or after they give birth. Trauma-related disorders, anxiety and depression can all be…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

President Putin Orders Coronavirus Vaccination to Begin

December 7, 2020

December 7, 2020 12:05:56

President Vladimir Putin of Russia has ordered that health officials in the country begin coronavirus vaccinations next week. The country has manufactured about 2 million doses of its vaccine.

President Putin’s statement was made on the same day that Britain gave its seal of approval for the BioNTech-Pfizer vaccine to be made available to…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Upcoming Investor Webcast

December 7, 2020

December 7, 2020 10:18:02

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological crop protection for high value crops, today announced an upcoming live webcast for its investment community. According to the update, MustGrow is poised to capitalize in 2021 and beyond in a rapidly growing market as regulatory framework moves to favor organic biopesticides and bioherbicides. The webcast is scheduled to take place at 11:00 a.m. ET on Wednesday, Dec. 9, 2020. Interested parties may visit https://ibn.fm/9Jz3E to register for the event and are asked to join five minutes before the beginning of the webcast.

To view the full press release, visit https://ibn.fm/QZ9Ny

About MustGrow Biologics Corp

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific Inc. (BRSF) Well Positioned Within Growing EEG Equipment Market

December 4, 2020 12:34:57

Recent report estimates EEG equipment market will grow at 4.5% CAGR reaching $1.99 billion by 2026
Driving forces include aging population, technological advances, increased use in neonatal intensive care units
BRSF well-placed to capitalize on market’s robust growth

A recent report published by Allied Market Research estimates that the global electroencephalography (“EEG”) equipment market was $1.4 billion in 2018 and is expected to reach $1.99 billion by 2026, growing at a CAGR of 4.5% from 2019 to 2026 (https://ibn.fm/Jmxjq). As a commercial-stage, healthcare company dedicated to developing innovative medical devices in the neurological diagnostics space, Brain Scientific (OTCQB: BRSF) seems well placed to capitalize on the growing EEG equipment market.

The key driving forces behind the market growth include factors such as the aging population, which leads to the increase in demand for brain diagnostics due to neurological diseases, as well as the increase in adoption of EEG equipment in surgery centers coupled with technological advancements in this field. In addition, the rise in the incidence of neurological disorders such as…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) to Showcase NeuroCap(TM) at AES2020

December 4, 2020 11:37:52

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, today announced that it will participate in AES2020 – the all-new virtual event for epilepsy professionals in academia, clinical practice, industry and advocacy. Slated to take place on Dec. 4–8, 2020, the American Epilepsy Society’s Annual Meeting is the largest meeting and exhibition in the world to share common scientific and clinical interests in epilepsy and clinical neurophysiology. “Brain Scientific has successfully taken part in AES conferences before, and this year we will have a virtual booth at this important event. We will be showing the new version of our disposable NeuroCap(TM) with Velcro elements to hundreds of specialists from around the world,” said Irina Nazarova, marketing director at Brain Scientific. “Our NeuroCap(TM) is designed to be safe, comfortable and sanitary, with no cleaning or scrubbing required. It takes 5 minutes or less to apply.”

To view the full press release, visit https://ibn.fm/SfmN0

About Brain Scientific

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

University of Delaware Receives $11 Million NIH Research Grant

December 4, 2020 11:05:25

The National Institutes of Health extended the COBRE grant valued at over $11 million for the University of Delaware biomedical research team. This will allow the team to proceed to phase 2 of their research.

The Center of Biomedical Research Excellence grant is centered on finding therapeutic leads and chemical probes. The research team is led by…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) Investee Company, PowerTap, Hires NASA-Based Firm to Engineer Hydrogen Production Unit

December 4, 2020 10:50:39

PowerTap Hydrogen Fueling Corp. (“PowerTap”) engages services of NASA-based hydrogen engineering firm, Cryotek
Hydrogen fuel cell vehicle market forecasted for CAGR of 66.9% from 2019 to 2026 and projected to reach $42 billion by 2026, according to Allied Market Research (https://ibn.fm/ejitO)
PowerTap plans to install an initial 500 hydrogen filling stations in California and an additional 500 hydrogen filling stations over next three to five years in other parts of the USA.
Clean energy expert Greg Nuttall appointed to the PowerTap advisory board.

The announcement by Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) that its investee company, PowerTap, has engaged NASA-based hydrogen engineering firm, Cryotek, as an engineering design partner will give an added fillip to the value of Clean Power’S investment in the fast-growing hydrogen fuel-cell vehicle market. Clean Power Capital is an investment holding company with investments in the health industry and renewable energy industry, has recently increased its focus on opportunities in the renewable energy industry, including fuel-cell technologies. The collaboration between PowerTap and Cryotek will advance PowerTap’s efforts to commercialize its patented hydrogen filling technology, and therefore increase the value of Clean Power’s investment in fuel-cell technologies and PowerTap.

PowerTap is aiming to deploy hydrogen fueling units at existing truck stops and gas stations across the USA, with an initial deployment of up to 500 units in California. Including the initial expansion of up to 500 stations in California, PowerTap has set a target of up to 1,000 stations stations in total, within the next three to five years throughout the USA. To bolster its expertise in…

NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

About Green Car Stocks

Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at LD Micro Main Event

December 3, 2020

December 3, 2020 15:28:00

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will participate in the LD Micro Virtual Main Event 2020 Conference. According to the update, 180 Life Sciences CEO Dr. James Woody is scheduled to present at 1:40 p.m. EST on Tuesday, Dec. 15. Interested parties should visit https://ibn.fm/KHrgf to register for the event. The 2020 LD Micro Main Event will feature a new and unique format with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.

To view the full press release, visit https://ibn.fm/TGP4z

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present Overview, Clinical Trial Update at Upcoming Benzinga Conference

December 3, 2020

December 3, 2020 12:52:02

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will present at the Benzinga Global Small Cap Conference taking place virtually on Dec. 8-9, 2020. Genprex’s president and CEO, Rodney Varner, will deliver a company overview that includes recent progress the company has made on its upcoming Acclaim-1 clinical trial. Varner’s presentation is scheduled to begin at 2:30 p.m. EST on Tuesday, Dec. 8. Investors and other interested parties should visit https://ibn.fm/VdFrh to register for the event.

To view the full press release, visit https://ibn.fm/EPK3b

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s web site atwww.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Risks Associated with Prolonged Sitting Can Be Counteracted by Engaging in Physical Activity

December 3, 2020

December 3, 2020 12:05:37

Recent guidelines introduced by the World Health Organization (WHO) on sedentary behavior and physical activity show that indulging in weekly physical activities can neutralize the health harms linked to prolonged sitting. These guidelines were reported in as special issue of “British Journal of Sports Medicine.” The article notes that all physical activity is good for a person’s health in the long term.

This is the first time that such recommendations have been made, which indicates that there’s…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Files Patent Application for Flexible EEG Cap

December 2, 2020

December 2, 2020 11:18:24

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has filed a provisional patent application in the United States Patent and Trademark Office (“USPTO”) entitled, “FULL HEAD APPARATUS AND ELECTRODES FOR CONDUCTING ELECTROENCEPHALOGRAPHY.” “The new EEG product for which Brain Scientific is seeking a patent approval is a flexible head cap for conducting electroencephalography,” said BRSF Marketing Director Irina Nazarova. “The cap carries multiple dry electrodes that are placed at various positions corresponding to various channels for bio-signal collection.”

To view the full press release, visit https://ibn.fm/jarkd

About Brain Scientific

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Find That Hypertension Increases Brain Damage Risk with Age

December 2, 2020

December 2, 2020 11:05:36

A research study conducted by Centre for Prevention of Stroke and Dementia clinical research fellow Dr. Karolina Wartolowska investigated the presence of white matter hyperintensities in the brain. These hyperintensities usually highlight small blood vessels that may be damaged and that manifest on MRI scans as bright regions. This damage is said to increase with blood pressure and age; the damage is linked to a decrease in cognitive function and an increased risk of depression, physical disabilities, dementia and stroke.

The study involved 37,041 individuals enrolled in the UK Biobank. A huge chunk of the participants was recruited from the…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Reschedules Special Stockholder Meeting, Urges Stockholder Voting

December 2, 2020

December 2, 2020 10:55:44

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that its virtual Special Meeting of Stockholders, which was scheduled for Dec. 1, 2020, was held but no business was conducted because a full quorum was not in attendance. The meeting has been rescheduled for Dec. 30, 2020 at 3 p.m. CST. Arrangements have been made for stockholders can attend via a live audio webcast, allowing more opportunity for stockholders to vote on proposals outlined in the definitive proxy statement filed by Predictive Oncology with the Securities and Exchange Commission (“SEC”). The Special Meeting record date will remain Oct. 28, 2020. POAI management and board members encourage stockholder Stockholders of record to vote, regardless of whether they attend the meeting. Stockholders can vote in several ways: at the reconvened Special Meeting, by proxy using the proxy card included with POAI’s definitive proxy statement, or by proxy via facsimile, email or through the internet. Stockholders who have already voted need not take any action unless they want to change their vote.

To view the full press release, visit https://ibn.fm/AisaX

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) Advances Brain Cancer Drug Candidate and Sponsors Annual SNO Conference

December 1, 2020 14:49:10

Biotechnology developer CNS Pharmaceuticals is preparing, with its partner WPD Pharmaceuticals, a global set of Phase 2 trials for its drug candidate Berubicin, which has shown promise in combating the effectively fatal glioblastoma multiforme (“GBM”) brain cancer
Since another company conducted Phase 1 safety trials for Berubicin 14 years ago, one patient has survived cancer-free while two others saw reductions in tumor size of up to 80 percent
The Phase 2 trials will build on the Phase 1 results, conducting targeted testing that offers side-by-side comparison between Berubicin and chemotherapy drug lomustine in real time beginning next year
The company is also preparing with WPD to conduct the first Phase I trials of Berubicin in children in Europe
CNS Pharmaceuticals officers recently participated virtually in the annual Society for Neuro-Oncology (“SNO”) Scientific Meeting and Education Day to promote their work and discuss the progress of clinical trials

While the world’s attention remains occupied with developments related to the global coronavirus pandemic that has infected about 60 million people and claimed the life of nearly 1.5 million of them (https://ibn.fm/ki9Vf), a dedicated group of researchers continues to pursue breakthroughs on the nearly always fatal glioblastoma multiforme (“GBM”) type of brain cancer. Recently, the Society for Neuro-Oncology (“SNO”) held its 25th Annual Scientific Meeting and Education Day to spotlight the efforts of over 2,600 researchers and clinician scientists from more than 40 countries in researching and treating GBM and similar brain cancers (https://ibn.fm/WCLpE).

CNS Pharmaceuticals (NASDAQ: CNSP) appeared at the virtual conference through a joint sponsorship with WPD Pharmaceuticals, staffing a booth in the virtual exhibit hall while Dr. Patrick Wen, a member of CNS’s Science Advisory Board, participated in a panel discussion on clinical trials during the plenary session Nov. 20, and in online poster presentations throughout the…

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Releases Test Results for Control of Threat to $25 Billion Banana Industry

December 1, 2020 13:23:28

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has announced initial test results of its mustard-derived organic biopesticide formulation designed to control Fusarium wilt TR4, a destructive pathogen threatening the global banana industry, which is valued at $25 billion. Completed via third-party independent laboratory CyberAgrot SAS in Colombia, the testing reported 100% control Fusarium wilt TR4, known as Panama disease. The disease led to the declaration of a national state of emergency in Colombia in 2019. Based on what the company has been able to determine, complete control of this disease has never been achieved. The company is now planning more advanced testing of the product in greenhouse and field settings, which could lead to registration and use in Colombia and other countries that produce bananas. Following ICA official protocols, samples treated with MustGrow’s natural organic biopesticide showed 100% control of Fusarium wilt TR4 while control samples the didn’t use the biopesticide showed Fusarium wilt TR4 growing. “The CyberAgrot team is very pleased with the recent laboratory results of MustGrow’s mustard-derived product,” said CyberAgrot general manager Alexander Chajin Robles in the press release. “This work further advances MustGrow towards our shared goal of combating the Panama Disease, which has devastated the Banana Industry in Colombia and across the globe. Eliminating the disease is a national priority for the Colombian government, with the disease now affecting acres in many regions of Colombia. MustGrow’s product achieved 100% control of Fusarium wilt TR4 and we very much look forward to now begin field trials. With further success, we will advance conversations with the Colombian Agriculture regulatory body as well as the Colombian Banana Association, accelerating MustGrow’s product as the only 100% organic solution to a growing crisis.”

To view the full press release, visit https://ibn.fm/EmItE

About MustGrow Biologics Corp.

MustGrow is a publicly traded, agriculture biotech company focused on providing natural, science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a U.S. EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s Pest Management Regulatory Agency (“PMRA”) as a biopesticide for high-value crops, including fruits and vegetables. MustGrow has now concentrated a liquid format, TerraMG, that with regulatory approval could be applied through standard drip or spray equipment, improving functionality and performance features. The company has approximately 37 million basic common shares issued and outstanding. For more information about the company, please visit www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Create Portable, Low-Cost MRI Scanner

December 1, 2020 12:05:20

If you’ve ever had to get a scan to assess for head trauma, then you probably had an MRI. The immobile and costly procedure is also used to detect brain cancer. To help make this diagnostic option more accessible, a group of scientists led by researchers from the Massachusetts General Hospital has created a portable, compact, low-cost MRI scanner.

This scanner can be located in a doctor’s office or small clinics or installed in an ambulance. The portability of this power head only scanner also allows it to…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Commences Site Recruitment for Upcoming Acclaim-1 Clinical Trial

December 1, 2020 10:33:01

Genprex (NASDAQ: GNPX), focused on developing life-changing therapies for patients with cancer and diabetes, on Monday announced its commencement of clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (“NSCLC”). The company’s timing of patient recruitment and enrollment keeps it on track for its Acclaim-1 clinical trial to commence in the first-half of 2021. “Our clinical team is engaging with prestigious cancer centers and research institutions across the U.S. to ensure we select optimal study sites, which play an important role in the success of a clinical trial,” said Rodney Varner, president and chief executive officer of Genprex. “We look forward to working with leading clinical investigators who will help drive our mission to bring forth a treatment for advanced lung cancer patients.”

To view the full press release, visit https://ibn.fm/zxX8J

About Genprex Inc.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine

December 1, 2020 09:58:36

VistaGen Therapeutics (NASDAQ: VTGN) has appointed a new vice president of translational medicine. A pioneer in the development of neuroactive steroids known as pherines, Louis Monti, MD., PhD., developed the original scientific platform that enabled the early research and development of VistaGen’s PH94B and PH10. The two intranasal neuroactive steroid drug candidates (pherines) have potential for the rapid-onset treatment of anxiety and depression disorders, respectively. VistaGen is a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Throughout his career, Monti has researched neuroactive pherines and their potential as a treatment for anxiety and depression. His new role at VistaGen allows him to continue to assist with the late-stage clinical development of PH94B and PH10 as well as employ his impressive R&D background in working with neuroactive steroids to discover expansion opportunities for the company. “We have had the pleasure of working closely with Dr. Monti in a consultative capacity since 2018 to complement our efforts to develop PH94B and PH10 to improve the lives of millions of people worldwide who suffer from anxiety and depression disorders every day,” stated VistaGen CEO Shawn K. Singh in the press release. “As we approach several potentially significant milestones for these differentiated neuropsychiatric drug candidates in 2021 and beyond, Dr. Monti’s unique knowledge, expertise, and insight about their potential, as well as potential opportunities for further expansion of our CNS pipeline, will be valuable. We are excited that he has now joined us as a full-time member of our R&D team.”

To view the full press release, visit https://ibn.fm/YaS3C

About VistaGen Therapeutics Inc.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Agreement for Expansion into EU Market

November 30, 2020 15:27:05

Brain Scientific’s (OTCQB: BRSF) Vice President of Marketing, Stuart Bernstein, has written an article for Health Care Business News titled, “COVID’s influence on neurology drives need for disposable technologies.” The piece discusses increased concern for health care and frontline workers treating emergent cases for COVID-19 patients developing neurological symptoms and conditions, as well as a critical need for testing solutions. The article reads, “Sudden onset of seizures, metabolic encephalopathy, stroke and other neurological conditions can negatively impact COVID patient outcomes and morbidity rates. Growing evidence of the commonality of neurological symptoms in COVID patients, coupled with challenges in accessibility, efficiency and sanitation of EEG administration reveals an urgent need for broader access to disposable neurological testing equipment. Disposable EEG headsets offer a solution which can be integrated easily into current standard-of-care and pair with clinical-grade EEG devices to acquire, record, transmit and display a patient’s electrical brain activity. Disposable equipment for neurological testing is well-positioned to address several challenges facing hospitals and urgent care facilities today.”

To view the full press release, visit https://ibn.fm/IHnkN

About Brain Scientific

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Preclinical Data for Potential Anxiety Treatment

November 30, 2020 14:50:05

VTGN CEO “even more excited about PH94B’s potential to change lives without the risky side effects and safety concerns of benzos”
Study results suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation, cognitive impairment or abuse liability
Company making significant progress in preparing PH94B for launch of pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder

VistaGen Therapeutics (NASDAQ: VTGN) has reported new preclinical findings differentiating the mechanism of action of PH94B from that of benzodiazepines (https://ibn.fm/Al4ur). PH94B is an intranasal neuroactive steroid VistaGen is preparing for Phase 3 development as a potential acute rapid-onset treatment of anxiety in adults with social anxiety disorder. As a solution to anxiety notably lacking the notorious side effects of traditional medications, the formulation could be a game-changer to the world of mental health.

“We are very pleased with the results of these studies that suggest PH94B’s mechanism of action may not have benzodiazepine-like side effects, such as sedation and cognitive impairment, or abuse liability,” said VistaGen CEO Shawn K. Singh…

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Psychologist Explains Reason Behind Reckless Behavior Amid Worsening Pandemic

November 30, 2020 11:05:32

In the last month, COVID-19 cases have increased significantly in New Jersey and Pennsylvania. The recent numbers top the figures recorded during the first wave of the coronavirus when the pandemic first hit. The rising numbers isn’t the most puzzling factor about this; more puzzling may be the fact that, despite the rising cases, people continue to make plans to meet up with family and friends during the upcoming Thanksgiving holiday, instead of social distancing.

To help contain the contagion, officials in Philadelphia introduced restrictions last week that limited…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Advancement of MS1819 Combination Therapy Trial in Turkey

November 30, 2020 11:03:31

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that the first two patients have been dosed in Turkey for its Phase 2 trial. The trial evaluates its investigational drug, MS1819, in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”), for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). “In the midst of a global pandemic and unpredictable obstacles, we are very encouraged to see our combination therapy trial moving forward at one of the clinical testing sites in Turkey,” said James Sapirstein, president & CEO of AzurRx. “We expect to release topline results in the second quarter of next year. We are optimistic the results will build on the encouraging data we received earlier this year and hope we will be one step closer to improving the lives of thousands of patients suffering from cystic fibrosis.”

To view the full press release, visit https://ibn.fm/XGBwo

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Why Brain Scientific Inc. (BRSF) Is ‘One to Watch’

November 25, 2020 15:15:35

Brain Scientific (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. The company’s mission is to modernize brain diagnostics by employing leading-edge technologies to bridge the widening gap in access to quality care. A recent article discussing the company reads, “Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

To view the full article, visit https://ibn.fm/oHY3a

About Brain Scientific Inc.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Trxade Group Inc.’s (NASDAQ: MEDS) Platform Meets Today’s Demands Through Intelligent Design

November 25, 2020 14:46:04

Trxade Group NASDAQ: MEDS), an integrated drug-procurement, delivery and health care platform, is ideally situated as the global pandemic has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services. Trxade Group’s business model appears to aptly and effectively meet today’s demands, largely demonstrated by the company’s revenue growth that has far exceeded expectations. A recent article discusses intelligent design of the Trxade platform that meets current standards of care while prioritizing information flow to assist both patients and providers. The article reads, “The company’s artificial intelligence API is designed to streamline the transfer of information between health care industry businesses. Trxade’s model thereby helps smaller, independent pharmacies in particular to competitively serve patients in spite of the proliferation of large pharmaceutical chains.”

To view the full article, visit https://ibn.fm/CTgt8

About Trxade Group Inc.

Headquartered in Tampa, Florida, Trxade Group is an integrated drug-procurement, delivery and health care platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making health care services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms: (1) the Trxade B2B trading platform with 11,725 registered pharmacies; (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division; (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail-order delivery. For additional information, please visit www.Trxade.com, www.DelivMeds.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Provide Digital Therapeutics Solution to Employees of Fortune 500 Company

November 25, 2020 12:32:11

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, will be providing its digital therapeutics solution to qualified employees of a U.S.-based Fortune 500 technology company. The contract, which goes into effect on Jan. 1, 2021, with the beginning of a new benefits year, calls for Dario to provide its digital diabetes tools and coaching to employees and their dependents. “We believe that employees will benefit from Dario’s unique therapeutic approach, which delivers adaptive, personalized experiences designed to drive behavior change through intuitive, clinically proven digital tools and coaching,” said DarioHealth president and North America GM Rick Anderson in the press release. “These employees will join a community of tens of thousands of members who engage with Dario every day to measurably improve their health. This contract was awarded through a request for proposal (“RFP”) process that included Dario’s largest competitors, and we believe it represents an important milestone in our strategic shift toward the business-to-business-to-consumer (“B2B2C”) market comprised of self-insured employers, healthcare provider networks, and insurance plans. We believe this further validates the competitive strength of our top-rated digital chronic care solution and will serve as an important market reference in converting our employer pipeline.”

To view the full press release, visit https://ibn.fm/ddd7y

About DarioHealth Corp.

DarioHealth Corp. is a leading, global digital therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new chronic conditions and geographic markets, using a performance-based approach to improve the health of users managing chronic disease. For more information about the company, please visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology’s (NASDAQ: POAI) Skyline Medical Sells 15 Streamway(R) Systems in Q3 2020 as COVID-era Drives Need for Sanitation Systems

November 25, 2020 11:05:51

Closed design of Streamway(R) System provides safety from potential hazards of drips and spills during endoscopy, radiology, cystoscopy, urology procedures
The Streamway(R) System reduces costs, minimizes environmental impact of 50 million potentially disease-infected canisters disposed into landfills
POAI’s Skyline Medical sells 8 Streamway(R) Systems to large university hospital in Virginia, 15 sold halfway into Q3 2020

In the age of COVID-19, the need for sanitation and safety during hospital procedures has reached an all-time high. Health professionals have reported an inhibited level of performance due to a lack of protection, comfort, and increased fatigue during surgery (https://ibn.fm/87UEr). Sanitary disposal systems, able to offer maximum protection to healthcare workers, have become incredibly necessary—and companies like Predictive Oncology are answering the call. Produced by Skyline Medical, a subsidiary of Predictive Oncology (NASDAQ: POAI), the patented Streamway(R) System features an entirely closed design, ensuring that medical professionals are safe from the potential hazards of drips and spills. It’s the first FDA-cleared direct-to-drain fluid disposal system that is designed specifically for medical applications such as endoscopy, radiology, cystoscopy and urology procedures. The proprietary system automates the collection, measurement and disposal of potentially infectious waste that includes blood and irrigation fluids. By connecting directly to a facility’s plumbing system, the Streamway(R) System has the potential to change the way healthcare facilities manage fluid disposal by… Read More>> NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Microorganisms Found in Child’s Bed Dust May Boost Their Health

November 25, 2020 11:05:39

In collaboration with the Gentofte Hospital and the Danish Pediatric Asthma Center, University of Copenhagen researchers from the Department of Biology have discovered a connection between children’s bacteria and the microorganisms that exist in the beds of children in an extensive study.

This link implies that the microorganisms may decrease the risk of a child developing…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

AzurRx BioPharma Inc. (NASDAQ: AZRX) Planning to Test Immediate Release MS1819 Capsules in Cystic Fibrosis Study

November 25, 2020 10:50:06

The company plans to add another study arm to its ongoing Phase 2b OPTION 2 clinical study which currently tests delayed release capsules
If it receives FDA approval, AzurRx would be able to identify the optimal delivery method for its drug candidate MS1819 without significant extra costs or delays
Enrollment in this arm of the study could begin as early as December 2020

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, has submitted a protocol amendment request to the U.S. Food and Drug Administration that would allow it to test immediate release capsules of its exocrine pancreatic insufficiency drug candidate MS1819.

According to a company press release, if the amendment is approved, AzurRx would modify its current Phase 2b OPTION 2 trial of MS1819 in cystic fibrosis patients to add a study arm that…

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) IND Application for Cancer Drug Berubicin Accepted for Review

November 25, 2020 10:20:24

CNS Pharmaceuticals wants to obtain FDA authorization for an Investigational New Drug application for drug candidate Berubicin, a novel treatment for Glioblastoma Multiforme
Company believes it’s on track to start in Q1 2021 a potentially pivotal Phase II Berubicin trial with adult GBM patients who have failed their primary treatment for the disease
Separately, a Phase II adult trial and a first-ever Phase I pediatric trial are slated to begin in 2021 in Poland in collaboration with sub-licensee partner, WPD Pharmaceuticals
Members of CNS’s management team attended A.G.P.’s Virtual Health Symposium, meeting 1-on-1 with investors

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, recently announced that it has filed an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its lead drug candidate Berubicin. This application has been accepted for review (https://ibn.fm/6NnwH).

Berubicin is proposed for the treatment of Glioblastoma Multiforme (“GBM”), an aggressive form of brain cancer currently considered incurable, and may prove beneficial in treating other central nervous system malignancies. Since gaining the rights to Berubicin, and securing from…

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Ring Nasdaq Opening Bell

November 24, 2020 15:21:43

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that, in celebration of its recently completed initial public offering, it will ring the Nasdaq Stock Exchange opening bell on November 27, 2020. 180 Life Sciences CEO Dr. James Woody will be joined by members of the ATNF team for the virtual ceremony, which will begin at approximately 9:20 a.m. Eastern Time, and can be viewed live at https://ibn.fm/R4bwK, as well as on the Nasdaq MarketSite Tower in Times Square, at 43rd Street and Broadway, New York, NY. “I am honored to be ringing the Nasdaq opening bell on behalf of everyone at 180 Life Sciences. We are on a mission to develop novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University,” Dr. James Woody commented. “We are thrilled to mark the significant milestone of becoming a public company with a bell ringing ceremony and look forward to celebrating future milestones with our public shareholders.”

To view the full press release, visit https://ibn.fm/XWZPS

About 180 Life Sciences Corp.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Korea Biomedical Review Article

November 24, 2020 14:51:41

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a recent article published in the Korea Biomedical Review. The piece, titled “Yuhan emerges as global new-drug developer with $3.6 billion tech export,” discusses Yuhan Corp.’s (OCT: YUHNF) move to enter technology transfer deals with global pharmaceutical companies, including Janssen Biotech, Gilead Sciences Inc. (NASDAQ: GILD), Boehringer Ingelheim and Processa. The article reads, “Yuhan also made a $410.5 million contract with the U.S. Processa Pharmaceuticals in 2020 for transferring the technology of YH12852, a drug candidate for functional gastrointestinal disease. YH12852 treats functional gastrointestinal diseases after surgery by selectively acting on the 5-hydroxytryptamine receptor 4, which plays a key role in regulating movements and senses in the intestine.”

To view the full article, visit https://ibn.fm/a9Qj3

About Processa Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Stock2Me Podcast

November 24, 2020 13:52:09

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in InvestorBrandNetwork’s (“IBN”) latest episode of its Stock2Me Podcast. Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are revolutionizing business practices within their respective markets. AZRX president and CEO James Sapirstein joins IBN’s Stuart Smith in the latest episode to discuss how AzurRx is working to redefine the standard of care for patients living with cystic fibrosis and chronic pancreatitis. “AzurRx Bio has been around for five years. … Our main product, MS1819, is being studied in chronic pancreatitis and in the GI effects of cystic fibrosis,” Sapirstein stated in the interview. “The market for this particular product, in chronic pancreatitis, competing against pancreatic enzyme replacement therapy (‘PERT’), is about $1 billion outside of the United States and several hundred million dollars inside the United States. The other market is cystic fibrosis. It’s over a $2 billion market worldwide for PERT.”

To view the full press release, visit https://ibn.fm/uXWmJ

About AzurRx BioPharma Inc.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Brain Cancer Drug During Syndicated Broadcast

November 24, 2020 13:25:29

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, is featured in a recent NetworkNewsAudio (“NNA”) broadcast. During the broadcast, CNS Pharmaceuticals CEO John Climaco explains that the company has recently submitted an investigational new drug (“IND) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer drug, Berubicin. Climaco also discusses CNSP’s intent to begin Phase 2 trials of the drug during Q1 2021. The Phase 2 trial is designed to analyze the efficacy of Berubicin in treating patients with Glioblastoma Multiforme (“GBM”) whose primary treatment has failed. “Our laser focus from the beginning has been to start the next phase of the investigation of Berubicin for the treatment of this deadly disease as quickly as possible,” said Climaco in the press release. “Our team has worked tirelessly for the past year, making several inroads on our manufacturing and clinical efforts to achieve this important milestone. We believe we are optimally positioned to continue to execute our plan and initiate our Phase 2 trial in the first quarter of 2021. We continue to build on the positive results Berubicin demonstrated in the Phase 1 study in high grade gliomas and look forward to advancing its clinical development in these patients, with the end goal of addressing the unmet medical need of better treatment for patients diagnosed with GBM.”

To view the full press release, visit https://ibn.fm/lAERb

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Diamond Equity Research Emerging Growth Invitational

November 24, 2020 13:05:38

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it will participate at the Diamond Equity Research Emerging Growth Invitational taking place virtually on Dec. 1, 2020. According to the update, Genprex’s executive vice president and COO, Michael Redman, will virtually deliver a company overview to investors followed by a guided question and answer session. Redman’s presentation is scheduled to begin at 11:30 a.m. ET on Dec. 1. Interested parties may visit https://ibn.fm/buX50 to register for the webinar. A live audio webcast and archive of the conference presentation will be available for a period of time using the registration link.

To view the full press release, visit https://ibn.fm/SL8Zy

About Genprex Inc.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers Design Wearable Sensors That Can Detect Employee Fatigue

November 24, 2020 11:35:20

Scientists have been designing devices that detect a worker’s alertness. The aim of this? To monitor for fatigue. Fatigue in a work setting can cause injuries or accidents and sometimes even loss of lives. Various industrial disasters, such as the Chernobyl nuclear accident, have been linked to worker fatigue.

These wearable devices measures the breathing rate of their users as well as their muscle contractions, sweating and heart rate…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Outlines Investor Initiatives, Announces Conference Presentation

November 24, 2020 11:06:04

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, announced its upcoming investor awareness initiatives today. In addition, the company will be conducting a presentation today at the Future of Food Investment Conference; one-on-one investor meetings are also being scheduled for next week. According to the announcement, MustGrow’s key programs and catalysts include testing of its biopesticide, which is formulated to stop Fusarium wilt TR4, a disease pathogen ravaging the $25 billion global banana industry; filing of key patents and progress on proof-of-concept data related to a biological weed killer; and confirmation of more than 98% control of Clubrootspores in soil and on plants achieved in a 24-hour time frame. The announcement noted that, as synthetic chemicals continue to be banned or deregistered globally, the time for biopesticides as arrived. The U.S. Environmental Protection Agency supports the use of safer pesticides, and the European Commission has announced a goal to cut in half the use of chemical pesticides by 2030. In addition, there has been a surging interest in biopesticide and bioherbicide crop protection from agriculture companies, with one study projecting that the global biopesticide market size will double to $8.5 billion by 2025. MustGrow’s Future of Food Investment Conference presentation is scheduled for today (Nov. 24) at 1:50 p.m. ET.

To view the full presentation, visit https://ibn.fm/XvBwj

To view the full press release, visit https://ibn.fm/DKCAH

About MustGrow Biologics Corp

MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. The company has approximately 37 million basic common shares issued and outstanding. For further details, please visit www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

VistaGen Therapeutics (NASDAQ: VTGN) Seeks to Address Rising Incidence of Mental Health Disorders in United States

November 24, 2020 10:35:09

VistaGen currently developing three novel drug candidates designed to treat central nervous system disorders
Anxiety disorders have been found to affect 18.1% of the U.S. population; however, only 36.9% of those suffering receive treatment
Prevalence of depressive disorders in U.S. workplace is estimated to result in economic impact of over $210.5 billion per annum
COVID-19 pandemic has further exacerbated these conditions, with number of patients displaying anxiety symptoms rising by 93% YoY between January – September 2020

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications which go beyond the standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders. Anxiety disorders have been found to be the most common mental illness in the U.S., affecting 40 million adults in the United States age 18 and older, or 18.1% of the population. However, while most anxiety disorders are highly treatable, only 36.9% of those suffering receive treatment (https://ibn.fm/z00SV). Two of the most common mental health conditions, namely depression and anxiety, are estimated to cost the global economy $1 trillion each year—and these conditions have been further exacerbated during the COVID-19 pandemic (https://ibn.fm/tmPyO). A recent study carried out by Mental Health America found that… Read More>> NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Brain Scientific Inc. (BRSF) Has Three-Phase Plan to Improve Access to Neurological Care

November 23, 2020

November 23, 2020 15:19:38

BRSF is modernizing brain diagnostics with cost-effective, disposable solutions that help minimize risk of spreading disease
AI-assisted analysis allows for processing of relevant data in real time at high speed for early diagnosis, higher rate of successful treatments

Brain Scientific (OTCQB: BRSF) is modernizing brain diagnostics by employing cutting-edge tech to bridge the widening gap in access to quality care. BRSF is achieving this through cost-effective and disposable substitutes to existing solutions that improve patients’ access to neurological care.

Currently, BRSF is in phase two of a three-phase plan for development. Phase one of development occurred in 2018–2019 with the inception of portable, clinical-grade, easy-to-use neurological devices. The company’s two FDA-cleared products — NeuroCap(TM) and NeuroEEG(TM) — are delivered by MemoryMD Inc., a…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures Additional Patents, Significantly Strengthening IP Portfolio

November 23, 2020

November 23, 2020 12:40:02

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. According to the update, the company, on Nov. 20, 2020, received notice from the USPTO that it will publish application 62/722,263 “Method of treating frozen shoulder using an il-33/TNF bispecific antibody.” The patent application is a continuation of US Patent No. 10,500,2730 and, once granted, it will be assigned patent number US-2020-0338193-A 1. 180 Life Sciences also received a notice of acceptance for its US patent, “Method of treating early stage Dupuytren’s Disease,” with the application number 16/089,234 filed September 27, 2018. Publication is expected to occur on Feb. 11, 2020. Additionally, the company received notification that the EU has granted its application number 15726740.2, filed on Aug. 29, 2016, which will be granted Dec. 9, 2020. “The issuance of these additional patent assets significantly strengthens the IP portfolio governing our lead program,” said Dr. James Woody, CEO of 180 Life Sciences. “We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies. Having these most recent patents awarded, particularly in the EU, is important as it provides validation in the 12 largest countries in the EU, including the UK, and provides the platform to be able to expand clinical trials, commercialization and partnering efforts throughout Europe.”

To view the full press release, visit https://ibn.fm/mGAXk

About 180 Life Sciences Corp.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Protein May Be the Key to New Cancer Treatments

November 23, 2020

November 23, 2020 11:05:41

Scientists have discovered that Netrin-G1, a protein that plays a role in neuron development in the brain, also has a hand in the growth and development of pancreatic cancer. The study results show that this particular protein protects pancreatic cancer cells from a person’s immune system while also providing important nutrients.

Pancreatic cancer is among the hardest cancers to treat as its…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers May Have Found a New Way to Predict Cancer Susceptibility

November 20, 2020

November 20, 2020 13:05:24

A new study by researchers from the University of Birmingham suggests that environmental cancer-causing agents may be used to help understand effects of exposure in addition to helping predict the individuals who may be more susceptible to developing cancer.

Every individual has been exposed to low levels of radiation or substances that promote…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Featured in Simply Wall St Article

November 20, 2020

November 20, 2020 11:06:11

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, was featured in a recent Simply Wall St article. The piece, titled “Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?,” explores the rate of the company’s annual negative free cash flow (“cash burn”) and whether it should be concerning to shareholders. The article reads, “Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought AzurRx BioPharma’s cash burn reduction was relatively promising. Even though we don’t think it has a problem with its cash burn, the analysis we’ve done in this article does suggest that shareholders should give some careful thought to the potential cost of raising more money in the future.”

To view the full press release, visit https://ibn.fm/bL6D1

About AzurRx BioPharma Inc.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Research Finds That Masks Don’t Affect Lung Function When Exercising

November 20, 2020

November 20, 2020 11:05:11

A new study published in the “Annals of the American Thoracic Society” indicates that wearing a face mask does not diminish lung function. The team of Canadian and American researchers that worked on the study discovered that while individuals may experience an increase in shortness of breath when wearing a face mask, there was no factual evidence showing that masks decreased lung function. This applies even when masks are worn during heavy exercise.

Face mask prevalence has grown since the onset of…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) Outlines Plans for Advancing Drug It Hopes Will Beat Deadly Brain Cancer

November 19, 2020 14:17:27

Biotechnology developer CNS Pharmaceuticals is working to advance the clinical trials of a novel brain cancer-fighting drug candidate with the aim of developing a new, effective therapy for treating an otherwise incurable disease
The company plans a complex, multi-armed Phase 2 trial of its candidate Berubicin in hopes that the drug candidate may ultimately gain an expedited pathway to approval and registration from the FDA
The trial for combatting Glioblastoma Multiforme is expected to begin next year, and on Nov. 12 the company’s officers launched a webinar to provide information on how the trial will be designed
CNS Pharmaceuticals is also preparing, in partnership with its sub-licensee WPD Pharmaceuticals, for two additional trials of Berubicin to be conducted in Poland including the first-ever Phase 1 pediatric trial as well as a parallel Phase 2 trial in adults

A biopharmaceutical company working to find a better way of treating an aggressive form of brain tumor, Glioblastoma Multiforme (“GBM”), which is currently regarded as incurable and ultimately fatal, announced recently that its submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) has been accepted for review. It includes a novel clinical trial design it hopes will lead to a breakthrough, and on Nov. 12 company officers discussed the design for the upcoming Phase 2 U.S. trial in a webinar open to the public (https://ibn.fm/bV2e2).

“I would like to remind everyone that this upcoming Phase 2 trial will build on the success of the Phase 1 trial of Berubicin in which the clinical benefit response was 44 percent, including one patient … who had a durable complete response and is still alive and cancer-free today, 14 years after treatment with Berubicin, and another two patients with partial responses, who had reductions of greater than 25 percent in the size of their tumors,”…

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Research Shows That Healthy Sleep Patterns Decrease Heart Failure Risk

November 19, 2020 13:05:19

According to new research that was reported in “Circulation,” the American Heart Association journal, adults who had healthy sleeping patterns had a lower risk of heart failure. This was in comparison to grown-ups who had unhealthy sleep patterns.

Healthy sleeping patterns are characterized by waking up in the…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Presents Promising Dario DTx Study Results

November 19, 2020 11:56:35

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, presented results from a new clinical study of 940 members at the 20th Annual Diabetes Technology Society Meeting (“DTS”). According to the update, the results showed a marked reduction in the percentage of high blood glucose readings and in the average blood glucose readings in adults over the age of 65 years using Dario’s digital therapeutics platform (“Dario DTx”). “We believe that Dario’s DTx platform plays a role in driving behavioral modification and enhances adherence to diabetes and other chronic condition management in older adults,” said Yifat Hershcovitz, Ph.D., scientific and clinical director at DarioHealth. “The results show that the platform can significantly reduce the percentage of high blood glucose ratios and may facilitate significant improvement in clinical outcomes, leading to better health outcomes for older individuals with diabetes.”

To view the full press release, visit https://ibn.fm/cS0uf

About DarioHealth Corp.

DarioHealth is a leading, global digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. Dario’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario is one of the highest-rated diabetes solutions in the market, and its consumer-centric MyDario(TM) mobile app is loved by tens of thousands of members worldwide. DarioHealth is rapidly moving into new geographic markets to meet the needs of additional chronic conditions, using a performance-based approach to improve members’ management of chronic disease. To learn more about the company and its digital health solutions, visit www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Eating Early Has No Impact on Weight-Loss Efforts

November 19, 2020 11:05:21

According to ongoing research that was presented during a recent virtual meeting at the American Heart Association Scientific Session, it was discovered that limiting meals to early in the day didn’t affect the weight of overweight adults who have diabetes or prediabetes.

Associate professor of epidemiology, nursing and medicine at Johns Hopkins, Nisa M. Maruthur, the study’s author, stated that…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Joint Sponsor 2020 SNO Virtual Meeting

November 19, 2020 10:44:59

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, will be joint sponsoring the 2020 Society of NeuroOncology (“SNO”) Virtual Meeting. CNS will be sharing sponsorship with WPD Pharmaceuticals. The virtual event is slated for Nov. 19–21, 2020. The joint sponsorship includes a booth in the virtual exhibit hall and is categorized as a Supporter level. In addition, one of the panel discussions will feature a member of CNS’s Science Advisory Board; Dr. Patrick Wen will be part of the panel discussing clinical trials. That particular event is scheduled for Friday, Nov. 20. Wen will also participate in online poster presentations.

To view the full press release, visit https://ibn.fm/e8g03

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

New Genetic Analysis Technique Can Predict Possibility of Cancer Treatment Side Effects

November 18, 2020 13:05:44

Using a model developed at the Linköping University in Sweden, scientists can now predict the risk of any adverse effects on the bone marrow and blood status of cancer patients undergoing chemotherapy. This study may make it possible to utilize genetic analysis in identifying patients who have a high probability of side effects. The research was reported in “npj Systems Biology and Applications.”

Health practitioners find it difficult to strike a balance between…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Eating Too Many Eggs Increases Risk of Developing Diabetes

November 18, 2020 11:05:57

Globally, some of the most popular breakfast food includes eggs, be it boiled, poached or scrambled. However, new research shows that excessive consumption of eggs may increase your risk of diabetes.

The longitudinal study, which was conducted by researchers from the University of South Australia in collaboration with…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) Places MiQLab(TM) System in Penn Vet Microbiology Laboratory

November 18, 2020 10:39:51

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that it has placed a MiQLab(TM) system into the clinical microbiology laboratory at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet) as part of its Early Access Program. Penn Vet provides animal patient testing at the Ryan Veterinary Hospital and for patients of practices across the United States, processing thousands of samples each year. “We are very excited to be placing our first completed commercial MiQLab system in the Penn Vet microbiology laboratory for their evaluation,” said Dr. Jack Regan, LexaGene’s CEO and founder. “This is a tremendous step in delivering our technology into the veterinary market and beyond.”

To view the full press release, visit https://ibn.fm/Ri3T9

About LexaGene Holdings Inc.

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in A.G.P. Healthcare Symposium

November 18, 2020 10:09:53

CNS Pharmaceuticals (NASDAQ: CNSP) management will be participating in A.G.P.’s upcoming Virtual Healthcare Symposium. The symposium is scheduled for Nov. 19, 2020. Leaders of CNSP, a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, will be part of the event, which includes one-on-one virtual investor meetings. Potential investors who may want to attend the conference should contact an A.G.P. representative. CNS plans to start a Phase 2 clinical trial of its lead drug candidate Berubicin, which is designed to treat glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. The company owns the exclusive license to the Berubicin chemical compound worldwide; it also owns all data and know how regarding a completed Phase 1 clinical trial of the drug, which was conducted by Reata Pharmaceuticals in 2006.

To view the full press release, visit https://ibn.fm/OR9iD

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific Inc. (BRSF) Offers Stock to Wider Pool of Investors Through Dalmore Group

November 17, 2020 15:18:56

BRSF announce partnership with Dalmore Group
New product launch presents solution for growing need for rapid EEG testing due to COVID-19 pandemic
Brain Scientific shose to extend proposed Reg A+ offering to attract additional investors

Brain Scientific (BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, has announced a partnership with the Dalmore Group in a recent press release (https://ibn.fm/clcDx).

“We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein…

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

AzurRx BioPharma Inc. (NASDAQ: AZRX) Making Strides with MS1819 Clinical Trials for Cystic Fibrosis-Associated Pancreatic Insufficiency

November 17, 2020 14:57:14

Globally it is estimated that 70,000 people suffer from CF, with half the population in the United States
The global CF therapeutics market size was valued at $4.62 billion in 2018 and is expected to reach an estimated $9.3 billion by 2026
AzurRx BioPharma’s MS1819, currently undergoing clinical trials, is a promising therapy for severe exocrine pancreatic insufficiency in patients with cystic fibrosis

While still a relatively rare genetic disease, cystic fibrosis (“CF”) remains a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. This is why the need for innovative and effective therapies for the treatment of CF-associated ailments, such as AzurRx BioPharma’s (NASDAQ: AZRX) drug candidate for exocrine pancreatic insufficiency, is constantly growing.

According to Allied Market Research, the demand for effective treatment options is driving a global expansion of the CF therapeutics market. Further driven by the availability of personalized drug therapy and…

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Enters Strategic Agreement for Expansion into EU Market

November 17, 2020 13:30:30

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has entered into an agreement with Europe’s leading certification and compliance company AFINA s.r.o. Under the agreement, AFINA will act as an authorized representative for Brain Scientific in the European Union (“EU”) and assist with registering Brain Scientific’s advanced EEG solutions in 32 countries in the European market. “We believe our next generation rapid EEG product will be an invaluable solution for hospitals and medical centers across the EU,” said Boris Goldstein, chairman of the board at Brain Scientific. “We are delighted to move towards the ultimate goal of distributing our NeuroCap in Europe.”

To view the full press release, visit https://ibn.fm/45s2c

About Brain Scientific

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

California Researchers Develop Face Mask That Can Kill Viruses Once Exposed to the Sun

November 17, 2020 13:05:05

A team of Californian researchers has developed a cotton fabric that can release oxygen species that are reactive (ROS). The fabric does this when exposed to daylight, which kills microbes that are attached to the cotton fabric’s surface. The fabric is also washable, making it reusable and safe for its wearer. This research was reported in “The American Chemical Society Applied Materials & Interfaces” journal.

This news comes at a time when face masks being used are…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Requests Protocol Amendment to Phase 2b Study to Add Study Arm

November 17, 2020 12:50:47

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, will be submitting a protocol amendment request to the U.S. Food and Drug Administration (“FDA”) for its Phase 2b OPTION 2 trial of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. The proposed amendment requests the potential to add a study arm that uses an immediate-release MS1819 capsule. If approved, AZRX will be able to compare data from the existing arm that uses enteric (delayed-release) capsules with data from the new arm. Everything else regarding the study, including trial objectives, endpoints and statistical analysis, will remain the same. “We are pleased to announce that our OPTION 2 trial is well ahead of schedule and almost fully enrolled without any safety issues being observed,” said AzurRX chief medical officer James Pennington, MD, in the press release. “As this trial progresses, we believe there may be significant clinical value in adding a study arm that uses our immediate release capsules. Our intention is to identify the optimal delivery method and potentially provide additional scientific support and optionality for MS1819.”

To view the full press release, visit https://ibn.fm/Nj1Am

About AzurRx BioPharma Inc.

AzurRx BioPharma is a biopharmaceutical company specialized in the research and development of nonsystemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, consisting of MS1819 in conjunction with porcine-derived pancreatic enzyme replacement therapy, the current standard of care. The company is headquartered in New York, New York, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Q3 Numbers, Company Updates

November 17, 2020 12:21:30

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has released its financial results and provided business updates for the quarter ended Sept. 30, 2020. The report included a note that revenues of $0.5 million were level with the third quarter of last year, primarily driven through the sale of Predictive Oncology’s proprietary STREAMWAY product line. In addition, the company’s subsidiary, Soluble Biotech, moved into a new office and lab space and installed new equipment. POAI also signed its first contract with a pharmaceutical company for protein expression and solubility studies, and licensed 71 additional unique ovarian cancer cell lines from Ximbio, the world’s largest nonprofit dedicated to life science reagents of all kinds. “During the third quarter, we continued our work of laying a foundation for our precision medicine business,” said Predictive Oncology CEO Carl Schwartz, MD, in the press release. “We are making steady progress in our Helomics division with the launch of a restructured clinical test offering to clinicians for ovarian cancer. Our project with UPMC-Magee Womens Hospital, analyzing the genomic and drug response profiles of women with ovarian cancer to build predictive models’ terms of therapy response, is close to completion. We are also in discussions with several pharmaceutical companies about partnerships that will monetize our efforts. . . .Management continues to focus the majority of its resources on the company’s primary mission of applying artificial intelligence to precision medicine and to drug discovery. Our approach and the mediums used to replace rats and mice in preliminary cancer studies are working in three of our operating subsidiaries, Helomics, TumorGenesis and Soluble Biotech.”

To view the full press release, visit https://ibn.fm/Q6jl5

About Predictive Oncology Inc.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders

November 17, 2020 12:20:54

180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Monday released a letter to stockholders from its CEO Dr. James Woody. The letter addresses the closing of the merger with KBLM Merger Corp IV, which resulted in 180 Life Sciences now operating as a stand-alone publicly traded company with its common stock listed on the Nasdaq Capital Market under the symbol “ATNF.” In the update, Dr. Woody shares a little about himself and the world class team of scientists, physicians, and executives that now comprise the 180 Life Sciences management team and board of directors. He also discusses the company’s drug pipeline and plans moving forward, including what lies ahead and anticipated critical milestones. “I started my career in biotech as the Chief Scientific Officer and Senior Vice President of Research and Development at Centocor, where I led the team responsible for developing Remicade, the first of the TNF (tumor necrosis factor) inhibitor biologics,” Dr. Woody states in the letter. “This was in collaboration with Prof. Sir Marc Feldmann, one of the founders of 180 Life Sciences and the current Co-Chairman of the Board of Directors. Marc and I go back a long way, to the late 70s. Remicade was a breakthrough product, it was the first anti-TNF to show dramatic efficacy and triggered the ‘antibody revolution.’ According to a report in FiercePharma, Remicade sales topped $7 billion USD in 2016 and were $5 billion in 2019.”

To view the full press release, visit https://ibn.fm/HExHn

About 180 Life Sciences Corp.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Logistical Concerns Arise Over Extremely Low Temperatures Needed for COVID-19 Vaccine Storage

November 17, 2020 11:05:22

A few days ago, Pfizer announced that it had developed a coronavirus vaccine that had proven to be 90% effective in combating the virus in trials. However, to maintain the vaccine’s efficacy, the vaccine needs to be stored and transported at temperatures below -70º Celsius.

An infectious disease and vaccine specialist, Professor Gordon Dougan, from the University of Cambridge, explains that…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation Schedule for Upcoming Investor Conferences

November 16, 2020 14:22:41

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will participate in two upcoming investor conferences. According to the update, Processa will participate in one-on-one meetings at the Craig-Hallum Alpha Select Virtual Conference on Tuesday, Nov. 17, 2020, and the Benchmark Annual Discovery 1×1 Investor Virtual Conference on Wednesday, Nov. 18, 2020. Interested parties should contact their conference representative or [email protected] to schedule a one-on-one meeting with management.

To view the full press release, visit https://ibn.fm/biHn2

About Processa Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Physical Fitness in Children is More Important Than BMI

November 16, 2020 13:05:03

A new study by the University of Georgia has shown that while grown-ups exercise mostly to lose weight, children should exercise to build endurance, or how well their bodies can handle long periods of exercise. Physical education for children should be centered on motivating children to be active, educating them on the benefits of exercise and improving their physical skills.

According to the authors of the study, strengthening children’s cardiorespiratory endurance should be…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Predictive Oncology (NASDAQ: POAI) CEO Discusses Subsidiaries’ Proprietary Tech, Innovative Media

November 16, 2020 12:30:42

CEO expects results that will “build the stock and raise the stock price”
POAI focused on positioning TumorGenesis kits to manufacturers
Helomics has largest database of its kind in the world, brings cutting-edge technology to cancer research

During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones and outlined strategic goals. In addition, Schwartz provided key updates on the company’s four impressive subsidiaries: Skyline Medical, TumorGenesis, Soluble Biotech and Helomics.

“I’m very encouraged. I think we’re moving right along. Things never go as fast as we would like them, and it can be very frustrating at times,” Schwartz stated…

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Gene Marker Suggests Likelihood of Prostate Cancer Metastasizing

November 16, 2020 11:05:59

Researchers have found a genetic signature that can forecast whether cancer is likely to metastasize or spread in the early stages of localized prostate cancer. The signature can also predict whether the disease will respond to anti-androgen therapy. In addition, the new signature may be beneficial in helping evaluate the disease’s response to treatment as well as creating new treatments to treat or avert the advanced stages of prostate cancer. This groundbreaking study was reported in “Nature Cancer.”

A professor of cell biology and pathology in Columbia University’s Irving Medical Center, Cory-Abate-Shen, senior author of the study, states…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Annual General Shareholder’s Meeting Results, Secures Order for MiQLab(TM) System

November 16, 2020 10:51:45

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, on Friday announced the voting results of the company’s 2020 Annual General Shareholder’s Meeting held on November 10, 2020 in Vancouver, British Columbia. According to the update, a total of 48,273,080 common shares were voted at the meeting, representing 42.26% of the votes attached to all outstanding common shares of the company. All matters presented for shareholder approval at the meeting were duly authorized and approved.

In addition, LexaGene today announced its receipt of a purchase order for a MiQLab(TM) system from a multinational biotechnology company that generates billions in annual revenue. “Years ago, I recognized the life sciences sector lacked automated instrumentation that allows end-users to easily create a customized test. I’m excited to announce that we now have a commercial system available for sale to help solve this problem,” LexaGene’s CEO and Founder Dr. Jack Regan said in the news release. “It is very gratifying that our first sale will be to a company that wants our technology for open-access use. This is just the beginning. Over the coming weeks and months, we expect to continue to roll out our technology into the open-access market, as well as to the veterinary diagnostics market, and eventually the human clinical diagnostics market.”

To view the full press releases, visit https://ibn.fm/xdrBV and https://ibn.fm/R8K3L

About LexaGene Holdings Inc.

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Social Distancing Spikes Loneliness Among Older People

November 13, 2020 13:05:55

According to a new study by researchers from the University of Stirling, the social distancing measures introduced to help contain the coronavirus infection has affected the well-being of Scotland’s older population, increasing their feelings of loneliness.

The study discovered a connection between the worsening health and well-being of individuals over 60 years and the…

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q3 2020 Results, Provides Corporate Update

November 13, 2020 11:33:24

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products intended to provide treatment for and improve the survival and/or quality of life for patients with unmet medical needs or no alternative treatment, on Thursday released its financial results for the third quarter of 2020. In addition, Processa provided a business update via conference call, for which the replay may be accessed at https://ibn.fm/BdxSB or by dialing 877-481-4010 (Toll-free) or 919-882-2331 (International) and entering replay passcode: 38528. “The third quarter was a period of tremendous value creation. Over that time, we in-licensed important clinical drug candidates PCS12852 and PCS6422, uplisted to Nasdaq and closed a $19.2 million public offering,” Dr. David Young, CEO and chairman of Processa, stated in the press release. “Due to those achievements, we now have sufficient funds to complete three trials for three distinct markets, each exceeding $1 billion. Importantly, we are developing products for which existing clinical evidence of efficacy has already been established. With key milestones to announce over the next 12-18 months, including interim data for PCS6422 in 3Q21 and PCS499 in 4Q21, we are excited about the near-term opportunity of increasing shareholder value.”

To view the full press release, visit https://ibn.fm/VpuUK

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products for which existing clinical evidence of efficacy has already been established for unmet or under-served medical conditions for which patients need treatment options that improve survival and/or quality of life. The company used these criteria to develop its pipeline programs in order to achieve high-value milestones effectively and efficiently using the Processa Regulatory Science approach. The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Q2 Results, Provides Update on CNS Pipeline and Business Progress

November 13, 2020 10:34:44

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today reported its financial results for the fiscal 2021 second quarter ended September 30, 2020. In addition, the company provided an update on its CNS pipeline and business progress. “We see a significant rise in mental health concerns as the global COVID-19 pandemic continues to impact the daily lives of millions of individuals. We are committed to developing innovative therapies that provide relief to those suffering from anxiety and depression, and we are working diligently towards that goal,” said VistaGen CEO Shawn Singh. “We are making significant progress in preparing PH94B for launch of a pivotal Phase 3 study for acute treatment of anxiety in adults with social anxiety disorder in the second quarter of 2021. After reaching consensus with the FDA on the key components of the study design, it will be very similar to the statistically significant Phase 2 study of PH94B in social anxiety disorder. We are also working with the FDA to finalize details for our Phase 2A study of PH94B in adjustment disorder, which we are planning to initiate in early 2021.”

To view the full press release, visit https://ibn.fm/c1QvN

About VistaGen Therapeutics

VistaGen is a clinical-stage biopharmaceutical company developing and commercializing differentiated new generation medicines that go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Biodegradable Implantable Sensors Can Monitor Body Functions